Bile Acids & Your Gut Microbiome: Why Secondary Bile Acids Are Metabolic Master Switches

Primary Bile Acids: What the Liver Makes

Bile acid synthesis begins in hepatocytes via two competing pathways. The classical (neutral) pathway, governed by cholesterol 7α-hydroxylase (CYP7A1), produces the majority of bile acids under normal conditions. The alternative (acidic) pathway, driven by CYP27A1 and CYP7B1, is quantitatively minor but disproportionately important in disease states. Both converge on two primary bile acids: cholic acid (CA) and chenodeoxycholic acid (CDCA).

These are amphipathic steroids — one face hydrophobic, one hydrophilic — that form mixed micelles with dietary lipids in the small intestine. Before secretion into bile, they are conjugated (amidated) with glycine or taurine, yielding glycocholic acid, taurocholic acid, and their CDCA equivalents. Conjugation increases water solubility and keeps bile acids ionized at intestinal pH, preventing passive reabsorption in the proximal gut where they are needed for fat emulsification.

The average adult synthesizes 200–600 mg of bile acids per day from cholesterol, cycling this pool through the enterohepatic circuit approximately 6–10 times daily. But this tightly controlled primary chemistry is only the beginning of the story. The real metabolic complexity happens 300 cm downstream, in the colon, where microbes take over.

7α-Dehydroxylation: How Gut Bacteria Rewrite the Bile Acid Code

When conjugated bile acids reach the terminal ileum, roughly 95% are actively reabsorbed by the apical sodium-dependent bile acid transporter (ASBT) and returned to the liver via portal blood. The ~5% that escape this reabsorption pass into the colon, where a highly specialized microbial community performs chemistries that mammalian cells cannot.

The key transformation is 7α-dehydroxylation — the removal of the hydroxyl group at carbon-7, converting CA into deoxycholic acid (DCA) and CDCA into lithocholic acid (LCA). This biochemical step is performed by a restricted guild of anaerobic bacteria dominated by Clostridium scindens, which encodes the bai (bile acid inducible) gene operon. Only ~0.001% of colonic bacteria carry this operon, yet they drive the dominant chemical modification of the human bile acid pool (Ridlon et al., Gut Microbes, 2016).

Beyond 7α-dehydroxylation, gut bacteria perform a suite of additional biotransformations: deconjugation by bile salt hydrolases (BSH) expressed across many genera including Lactobacillus, Bifidobacterium, and Bacteroides; 7α/β-epimerization converting CDCA to ursodeoxycholic acid (UDCA); oxidation and epimerization at C-3, C-7, and C-12; and sulfation and glucuronidation. The result is a bile acid "fingerprint" that reflects the compositional state of the microbiome with remarkable sensitivity.

FXR and TGR5: Bile Acids as Hormones

For decades, bile acids were considered simple detergents. The discovery that they are potent ligands for nuclear and membrane receptors rewrote that view entirely. Two receptors dominate the biology.

FXR (Farnesoid X Receptor)

The farnesoid X receptor is a nuclear receptor expressed at highest levels in the liver, ileum, kidney, and adrenal gland. CDCA is its most potent natural ligand; CA, DCA, and LCA activate it with lower affinity. Upon bile acid binding, FXR heterodimerizes with RXR and drives transcription of a gene program that:

• Suppresses CYP7A1 (reducing de novo bile acid synthesis via SHP-mediated feedback)
• Induces FGF19 (fibroblast growth factor 19) in ileal enterocytes, which travels to the liver and reinforces CYP7A1 suppression via FGFR4/β-Klotho
• Upregulates ABCB11 (bile salt export pump, BSEP) to promote hepatic bile acid clearance
• Suppresses NTCP (sodium-taurocholate cotransporting polypeptide), reducing hepatic reuptake
• Activates lipoprotein lipase (LPL) and suppresses VLDL assembly, reducing triglyceride secretion

FXR also mediates potent anti-inflammatory signaling in the intestinal epithelium. Intestinal FXR induces angiopoietin-like protein 4 (ANGPTL4) and suppresses intestinal bacterial translocation. Loss of intestinal FXR signaling — as occurs when gut dysbiosis skews the bile acid pool toward species that are poor FXR agonists — accelerates intestinal permeability, endotoxemia, and systemic inflammation (Parseus et al., Gut, 2017).

TGR5 (Takeda G Protein-Coupled Receptor 5)

TGR5 (also called GPBAR1) is a membrane-bound G protein-coupled receptor activated by secondary bile acids — LCA and DCA are its most potent ligands, followed by CDCA and CA. TGR5 is expressed on macrophages, adipose tissue, enteroendocrine L-cells, cholangiocytes, gallbladder epithelium, and brown adipose tissue. Its signaling drives three metabolically critical effects:

1. GLP-1 secretion. TGR5 activation in L-cells of the distal small intestine and colon stimulates GLP-1 and PYY release via cAMP-PKA signaling. This mechanism explains, in part, why ileal bile acid diversion (as occurs with Roux-en-Y gastric bypass) produces dramatic improvements in glycemic control independent of weight loss (Thomas et al., Cell Metabolism, 2009).

2. Thermogenesis in brown adipose tissue. TGR5 stimulation in BAT promotes type 2 deiodinase (D2) activity, converting T4 to the active T3, which increases mitochondrial uncoupling and energy expenditure. Bile acid supplementation in mice increases BAT thermogenesis and protects against diet-induced obesity.

3. Anti-inflammatory macrophage signaling. In Kupffer cells and circulating monocytes, TGR5 activation raises intracellular cAMP, activates PKA, and suppresses NF-κB-driven cytokine production (TNF-α, IL-1β, IL-6). This positions bile acid signaling as a physiological brake on hepatic and systemic inflammation.

Bile Acids Link Microbiome to Obesity, T2D, and Cardiovascular Disease

The bile acid-receptor axis sits at the intersection of every major cardiometabolic disease.

Obesity and Energy Balance

Obese individuals exhibit a characteristically altered bile acid pool: elevated DCA, reduced CDCA-to-CA ratio, and diminished UDCA. A landmark study by Haeusler et al. (Journal of Clinical Investigation, 2013) demonstrated that insulin resistance in human subjects correlates with suppressed FGF19, implying impaired ileal FXR activation. This creates a vicious cycle: poor FXR tone elevates CYP7A1 activity, shifts bile acid synthesis toward CA (a weaker FXR agonist), and further blunts the FXR-FGF19 axis.

The microbiome connection: germ-free mice have a larger, more hydrophilic bile acid pool, higher FXR and TGR5 tone, and are protected from diet-induced obesity (Sayin et al., Cell Metabolism, 2013). Colonization with specific microbiota normalizes the bile acid pool but also reduces TGR5-driven GLP-1 secretion and energy expenditure — demonstrating that some bile acid-modifying bacteria are metabolically disadvantageous for the host.

Type 2 Diabetes

Several convergent lines of evidence connect bile acids to glycemic control:

• Bile acid sequestrants (cholestyramine, colesevelam) lower HbA1c by 0.5–0.8% in T2D patients despite not increasing insulin secretion directly — an effect now attributed to altered ileal FXR activation and increased colonic GLP-1 via TGR5
• Metformin, the first-line T2D drug, partially works by increasing bile acid recirculation to the distal gut, amplifying TGR5-mediated GLP-1 release (Foretz et al., Diabetologia, 2019)
• Post-bariatric surgery, altered bile acid delivery to the distal gut — rather than caloric restriction alone — accounts for a substantial portion of remission in T2D

Cardiovascular Disease

Bile acids regulate plasma cholesterol through two channels: (1) they are synthesized from cholesterol, so increasing bile acid synthesis lowers hepatic cholesterol pools and upregulates LDL receptor expression; (2) FXR activation suppresses VLDL-TG assembly and promotes HDL function.

Elevated serum DCA is an independent predictor of cardiovascular events. In a prospective cohort of 2,135 individuals, tertile analysis showed a hazard ratio of 1.42 (95% CI 1.08–1.87) for major adverse cardiovascular events in the highest DCA tertile, after adjusting for traditional risk factors (Mayerhofer et al., European Heart Journal, 2020). The proposed mechanism involves DCA-induced vascular endothelial oxidative stress and macrophage foam-cell formation in atherosclerotic plaques.

Conversely, UDCA — the 7β-epimer of CDCA, produced by microbiome epimerization — has demonstrated atheroprotective effects in cell and animal models, reducing oxidized LDL uptake in macrophages and improving endothelial nitric oxide signaling.

Diet, Cholestyramine, and Natural Approaches to Reshaping the Bile Acid Pool

How Diet Shifts the Pool

Diet is the dominant modifiable determinant of bile acid composition. High-fat diets — especially those rich in saturated fat — drive three compounding shifts: (1) increased total bile acid secretion to emulsify fat, expanding the substrate available for microbial transformation; (2) enrichment of Clostridium scindens and related dehydroxylating bacteria, amplifying DCA and LCA production; (3) reduction in fiber-fermenting bacteria, lowering fecal pH and further favoring dehydroxylation (which operates optimally at pH 5.5–6.5).

Plant-based diets rich in soluble fiber produce the opposite effect. Fermentable fiber (inulin, pectin, beta-glucan) selectively expands Bifidobacterium and Lactobacillus, species with high bile salt hydrolase activity but no 7α-dehydroxylase. This increases the ratio of primary to secondary bile acids, elevates CDCA (an FXR agonist), and lowers luminal DCA concentrations. Cruciferous vegetables specifically induce the expression of CYP3A4 and UDP-glucuronosyltransferases, accelerating bile acid detoxification in the gut wall.

Cholestyramine and Bile Acid Sequestrants

Cholestyramine is a non-absorbable anion exchange resin that binds bile acids in the intestinal lumen, preventing their reabsorption. The clinical consequences follow predictably from our bile acid biology:

• LDL reduction (15–30%): Interrupted enterohepatic cycling forces upregulation of hepatic CYP7A1 and LDL-receptor expression
• Triglyceride increase (5–20%): Reduced FXR activation releases brake on hepatic VLDL synthesis — a clinically relevant side effect in patients with baseline hypertriglyceridemia
• GLP-1 increase: By driving unabsorbed bile acids to the distal colon, sequestrants amplify TGR5-mediated GLP-1 secretion — the mechanism behind colesevelam's glycemic benefits
• Constipation and nutrient malabsorption: Long-term use requires monitoring of fat-soluble vitamins A, D, E, K

Natural Bile Acid Modulators

UDCA/TUDCA: Ursodeoxycholic acid (UDCA) and its taurine conjugate (TUDCA) are hydrophilic bile acids with cytoprotective properties. UDCA displaces toxic hydrophobic bile acids from the pool, stimulates bicarbonate secretion ("bicarbonate umbrella"), and directly activates SIRT1 to promote mitochondrial function. TUDCA is a potent chemical chaperone that reduces ER stress and has shown benefit in NAFLD, PSC, and experimental models of neurodegeneration.

Berberine: The isoquinoline alkaloid berberine inhibits BSH-expressing bacteria in a selective manner, partly reshaping the bile acid pool, while simultaneously activating AMPK and inhibiting hepatic lipogenesis. A meta-analysis of 14 RCTs found berberine reduced LDL by 0.65 mmol/L and fasting glucose by 1.0 mmol/L vs. placebo.

Psyllium husk: Soluble fiber from psyllium acts as a weak bile acid sequestrant by viscous gel formation, while also feeding bile acid-deconjugating microbiota. The LDL-lowering effect (~7%) is additive with statins.

Obeticholic acid (OCA): A synthetic FXR agonist (6α-ethyl-CDCA) approved for primary biliary cholangitis. In NASH trials, OCA improved liver histology but increased LDL — a class effect of FXR agonism. It illustrates that indiscriminate FXR activation is not uniformly beneficial; receptor subtlety matters.

The Bottom Line

Bile acids are not passive digestive detergents. They are a class of hormone-like signaling molecules whose composition is co-written by the liver and by the gut microbiome, and whose downstream effects touch glucose metabolism, lipid homeostasis, energy expenditure, inflammation, and cardiovascular risk. The key transformation — 7α-dehydroxylation by a small guild of gut anaerobes — converts relatively inert primary bile acids into potent secondary bile acids that act on FXR and TGR5 with profound systemic consequences.

A high-fat Western diet biases this system toward elevated DCA, impaired FXR tone, reduced GLP-1 secretion, and increased cardiovascular risk. Cholestyramine and synthetic FXR agonists can pharmacologically redirect the system, but at the cost of notable side effects. The more durable and side-effect-free strategy is dietary and microbiome-targeted: reduce saturated fat, increase fermentable fiber, selectively supplement with strains that deconjugate rather than dehydroxylate, and consider TUDCA or berberine where indicated. The bile acid pool is plastic — it responds within days to dietary shifts — making it one of the most tractable levers in cardiometabolic medicine.